One of the hallmarks of Alzheimer’s disease is the formation of protein plaques and tangles between nerve cells. These are made of so-called beta-amyloid fragments that stick together and accumulate between nerve cells, disrupting their function.
These beta-amyloid plaques are the focus of many experimental treatments that researchers are currently developing. Below is a list, compiled by Alzheimer's News Today, of the experimental treatments targeting beta-amyloid plaques. More information about each potential treatment is available by clicking on the name of the compound.
ABvac40 is an active vaccine being developed by Araclon Biotech.It consists of a fragment of beta-amyloid protein called beta-amyloid 40. It is designed to elicit an immune response against beta-amyloid plaques.
ACI-24 is a liposome vaccine, being developed by AC Immune. It is based on a fragment of beta-amyloid protein called Aβ-15. It is designed to elicit an antibody response against aggregated beta-amyloid peptides.
For the full list of experimental treatments, including Gantenerumab, Neflamapimod, and PQ912, visit Alzheimer's News Today.